Developing a new drug for Chagas disease
Drug Discovery for Chagas Disease
This study is working on a new medicine to help people with Chagas disease by finding safe and effective ways to target the parasite that causes it, with the goal of improving treatment for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11021043 on NIH RePORTER |
What this research studies
This research aims to create a new medication for Chagas disease, which is caused by the parasite Trypanosoma cruzi and affects millions, primarily in Latin America. The researchers are focusing on compounds that have shown promise in laboratory tests for effectively targeting the parasite while minimizing side effects. They are utilizing advanced screening techniques to identify and optimize new drug candidates that can clear the infection. The project builds on previous findings and aims to improve treatment options for patients suffering from this disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Chagas disease, particularly those who have not responded well to existing treatments.
Not a fit: Patients who do not have Chagas disease or those who are already effectively treated with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for Chagas disease, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in developing new treatments for Chagas disease, but this approach focuses on novel compounds and mechanisms that have not been extensively tested.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Buckner, Frederick Simmons — University of Washington
- Study coordinator: Buckner, Frederick Simmons
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.